Overall, our results suggest that down-regulation of ERAP2 significantly blocks the tumorigenic ability of pancreatic cancer cells and significantly enhances the anti-pancreatic cancer activity of gemcitabine. Here, ERAP2 is linked to pancreatic neoplasm.